DNAJC5 (DnaJ Heat Shock Protein Family Member C5) <table class="infobox infobox-gene">
Overview ...
DNAJC5 (DnaJ Heat Shock Protein Family Member C5) <table class="infobox infobox-gene">
Overview DNAJC5 , also known as Cysteine String Protein (CSP) or Csp1 , is a member of the DnaJ/Hsp40 co-chaperone family encoded by the DNAJC5 gene on chromosome 20q13.33[@chamberlain2001]. Originally identified as a synaptic vesicle protein with a unique cysteine-rich "string" motif, DNAJC5 plays essential roles in protein folding, synaptic transmission, and neuronal survival. Dominant mutations in DNAJC5 cause adult-onset neuronal ceroid lipofuscinosis (ANCL), and the gene has been implicated in both Alzheimer's and Parkinson's disease[@noskov2014].
Gene Structure and Expression The DNAJC5 gene spans approximately 12.5 kb and contains 7 exons. It encodes a protein of 292 amino acids with a molecular weight of approximately 34 kDa.
Domain architecture:
N-terminal J domain : ~70 aa, HPD motif for Hsp70 interactionCysteine-rich string region : ~30 cysteines with palmitoylation sites (membrane association)C-terminal substrate-binding region : Client protein recognitionExpression pattern:
Primary : Neurons throughout the CNS and PNSHighest expression : Hippocampus (CA1-3, dentate gyrus), cerebral cortex, cerebellum (Purkinje cells)Cellular localization : Presynaptic terminals, synaptic vesicles, endoplasmic reticulumMolecular Function
Hsp70 Co-chaperone Activity DNAJC5 functions as a co-chaperone for Hsp70 family proteins:
J domain proteins : Recruit and stimulate Hsp70 ATPase activitySubstrate delivery : Bind unfolded/misfolded proteins for Hsp70-mediated refoldingHsp70 partners : Predominantly interacts with Hsc70 (HSPA8) in neurons[@brauner2012]
Synaptic Vesicle Function The cysteine string domain is critical for:
Synaptic vesicle anchoring : Palmitoylation targets DNAJC5 to vesicle membranesVesicle cycling : Essential for synaptic vesicle endocytosis and recyclingSNARE complex assembly : Facilitates formation of the SNARE machineryCalcium sensing : Regulates exocytosis through interaction with synaptotagmin
Protein Quality Control DNAJC5 participates in neuronal proteostasis:
Chaperone-mediated protein folding : Prevents aggregation of client proteinsER-associated degradation (ERAD) : Coordinates with Hsp70 for misfolded protein clearanceAutophagy regulation : Directs damaged proteins to autophagic pathwaysRole in Neurodegeneration
Adult-Onset Neuronal Ceroid Lipofuscinosis (ANCL) Dominant DNAJC5 mutations cause ANCL, a lysosomal storage disorder:
Mutation types : Missense mutations in the J domain (p.G117V, p.L175P)Pathogenesis : Impaired chaperone function leads to accumulation of lipofuscinClinical features : Progressive neurodegeneration, dementia, seizures, ataxiaInheritance : Autosomal dominant with incomplete penetrance
Alzheimer's Disease DNAJC5 is implicated in AD through several mechanisms:
APP processing : Hsc70-DNAJC5 complexes regulate APP trafficking through the secretory pathwayAβ generation : Altered DNAJC5 function affects amyloidogenic processingSynaptic dysfunction : Loss of DNAJC5 impairs synaptic vesicle cyclingProtein aggregation : Impaired chaperone function may contribute to tau and Aβ pathology
Parkinson's Disease
α-Synuclein interaction : DNAJC5 can modulate α-synuclein aggregation and clearanceLRRK2 pathway : DNAJC5 expression is altered in LRRK2-associated PDMitochondrial quality control : DNAJC5 contributes to mitochondrial protein foldingNeuroprotection : DNAJC5 overexpression protects against PD-relevant toxins
Other Neurodegenerative Conditions
Huntington's disease : DNAJC5 dysfunction contributes to mutant huntingtin toxicityAmyotrophic lateral sclerosis : Altered expression in motor neuronsSpinocerebellar ataxias : Interacts with ataxin proteinsClinical Significance
Genetic Diseases
Therapeutic Implications DNAJC5 represents a potential therapeutic target:
Chaperone enhancers : Small molecules that restore DNAJC5 functionGene therapy : Viral vector delivery to increase expressionProtein replacement : Not applicable (protein not secreted)Symptomatic approaches : Targeting downstream synaptic dysfunctionChallenges:
Dominant negative mechanism in ANCL complicates therapeutic approaches
Blood-brain barrier limits CNS delivery
Balancing chaperone activity without disrupting normal function
Key Interactions
See Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Chamberlain, L.H., et al, (2001) (2001)](https://doi.org/10.1074/jbc.M010838200)
[Noskov, L., et al, (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24567505/)
[Brauner, K., et al, (2012) (2012)](https://doi.org/10.1111/j.1471-4159.2012.07745.x) Show full description